摘要
目的 研究酚妥拉明联合利尿剂治疗对重症肺结核合并肺心病患者心功能指标的影响。方法 选取2021年6月—2023年12月期间在宁夏回族自治区第四人民医院收治的重症肺结核合并肺心病患者160例，随机分为对照组（常规治疗结合利尿剂）和观察组（酚妥拉明联合利尿剂治疗），每组各80例；比较两组的心功能指标、肺功能指标、临床症状改善情况以及凝血功能指标。结果 观察组治疗后的LVEF高于对照组，LVEDD、LVESD均低于对照组，差异显著（P <0.05）；观察组治疗后的FVC、FEV1均更高，而PASP、PaCO2均更低（P <0.05）；观察组的临床症状所需时间均短于对照组（P <0.05）；观察组治疗后的凝血功能指标优于对照组（P <0.05）。结论 重症肺结核合并肺心病患者经过酚妥拉明联合利尿剂治疗后，能显著改善其心功能和肺功能，缩短临床治疗时间，治疗效率显著提高，该联合治疗方案值得临床推广。
关键词： 酚妥拉明联合利尿剂；重症肺结核合并肺心病；心功能指标；影响
Abstract
Objective To study the effect of phentolamine combined with diuretic treatment on cardiac function indicators in patients with severe pulmonary tuberculosis and pulmonary heart disease. Methods 160 patients with severe pulmonary tuberculosis combined with pulmonary heart disease admitted to the Fourth People's Hospital of Ningxia Hui Autonomous Region from June 2021 to December 2023 were selected and randomly divided into a control group (conventional treatment combined with diuretics) and an observation group (phentola combined with diuretic treatment), 80 cases in each group; compare the cardiac function indicators, pulmonary function indicators, improvement of clinical symptoms and coagulation function indicators between the two groups. Results After treatment, the LVEF of the observation group was higher than that of the control group, and LVEDD and LVESD were lower than those of the control group, with significant differences (P <0.05); the FVC and FEV1 of the observation group after treatment were both higher, while PASP and PaCO2 were lower ( P <0.05); the time required for clinical symptoms in the observation group was shorter than that in the control group (P <0.05); the coagulation function index of the observation group after treatment was better than that of the control group (P <0.05). Conclusion After treatment with phentolamine combined with diuretics, patients with severe pulmonary tuberculosis and pulmonary heart disease can significantly improve their cardiac and pulmonary functions, shorten clinical treatment time, and significantly improve treatment efficiency. This combined treatment regimen is worthy of clinical promotion.
Key words： Phentolamine combined with diuretics; Severe pulmonary tuberculosis combined with pulmonary heart disease; Cardiac function indicators; Impact
参考文献 References
[1] 崔玉清. 酚妥拉明联合利尿剂治疗肺心病的临床疗效[J]. 当代临床医刊,2023,36(3):91-92.
[2] 马景丽,冯胜东. 左西孟旦联合酚妥拉明对肺心病合并右心衰竭患者心功能及B型尿钠肽水平的影响[J]. 实用中西医结合临床,2021,21(17):63-64.
[3] 刘艳芬,刘亚北. 左西孟旦治疗联合酚妥拉明治疗肺心病引起右心衰竭的临床分析[J]. 临床研究,2023,31(12):85-88.
[4] 赵小君,张琳. 低分子肝素钙联合酚妥拉明对肺心病患者凝血功能及心肺功能的影响[J]. 反射疗法与康复医学,2023,4(6):121-124.
[5] 袁章安,杨起,张娟. 多巴胺+酚妥拉明+复方丹参治疗重症肺心病心力衰竭患者80例临床分析[J]. 贵州医药,2021, 45(8):1259-1260.
[6] 林平龙. 肺心病难治性心衰患者急诊治疗中应用多巴胺联合酚妥拉明治疗的效果观察[J]. 北方药学,2022, 19(6): 137-140.
[7] 黄丽榄,罗晓琳,王启文. 多巴酚丁胺与酚妥拉明治疗肺心病并心力衰竭的疗效及护理分析[J]. 海峡药学,2021, 33(8): 108-109.
[8] 赖文文,许朝祥,林娜萍,等. 左西孟旦联合利尿剂治疗慢性肺源性心脏病严重心力衰竭疗效及不良反应分析[J]. 北方药学,2021,18(1):155-156.
[9] 唐萍. 多巴胺联合酚妥拉明加间歇应用利尿剂治疗肺心病临床疗效观察[J]. 世界最新医学信息文摘,2021, 21 (101): 197-198.
[10] 李静. 酚妥拉明联合川芎嗪注射液对肺心病心衰患者心肌微循环状态及血NF-κB、IL-1β水平的影响分析[J]. 医学理论与实践,2021,34(5):763-764.